z-logo
open-access-imgOpen Access
Rituximab treatment in a case of anti- synthetase syndrome with severe interstitial lung disease and acute respiratory failure
Author(s) -
Maria Cristina Zappa,
Tiziana Trequattrini,
F. Mattioli,
Rosario Rivitti,
Rossana Vigliarolo,
Antonella Marcoccia,
Giovanni D’Arcangelo
Publication year - 2019
Publication title -
multidisciplinary respiratory medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.72
H-Index - 28
eISSN - 2049-6958
pISSN - 1828-695X
DOI - 10.4081/mrm.2011.439
Subject(s) - rituximab , medicine , interstitial lung disease , respiratory failure , acute respiratory failure , disease , lung , respiratory system , intensive care medicine , lymphoma , mechanical ventilation
We present a case of severe interstitial pneumonitis, mild polyarthritis and polymyositis, and Raynaud's syndrome with the presence of anti-Jo-1 antibodies, which had been diagnosed as anti-synthetase syndrome. The presence, however, of anti-Ro/SSA antibodies led us to understand that we were dealing here with a more severe form of interstitial lung disease. The patient was treated for acute respiratory failure but he showed resistance to glucocorticoids and cyclosporine. Thus, he was treated with infusions of anti-CD20 therapy (rituximab): his clinical conditions improved very rapidly and a significant decrease in the activity of pulmonary disease was detected using high-resolution computerized tomography (HRCT) of the thorax and pulmonary function tests.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom